Trials / Completed
CompletedNCT01414101
Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 329993 in Subjects With Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Ionis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ISIS CRP Rx and its effects on CRP and other pharmacodynamic measures, versus placebo, in subjects with active rheumatoid arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ISIS CRP Rx or Placebo |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2011-08-11
- Last updated
- 2013-05-17
Locations
10 sites across 2 countries: Canada, Russia
Source: ClinicalTrials.gov record NCT01414101. Inclusion in this directory is not an endorsement.